文献速递肝病消化道肿瘤与早癌

内皮DGKG促进肝细胞癌肿瘤血管生成与免疫逃逸

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2023-10-12

该研究在肝细胞癌(HCC)肿瘤血管内皮细胞中筛选并验证二酰甘油激酶γ(DGKG)高表达,通过单细胞RNA测序、飞行时间流式细胞术及体内外实验发现内皮DGKG促进血管生成和调节性T细胞分化;缺氧下HIF-1α直接结合DGKG启动子激活其转录,DGKG通过招募USP16促进ZEB2去泛素化增加TGF-β1分泌;靶向内皮DGKG可增强PD-1与VEGFR-2双阻断疗效。

要点

  • 内皮DGKG在HCC肿瘤血管内皮细胞中高表达,促进血管生成和免疫抑制性调节性T细胞分化。
  • 缺氧下HIF-1α直接结合DGKG启动子激活转录,DGKG通过USP16/ZEB2/TGF-β1轴发挥作用。
  • 靶向内皮DGKG可增强PD-1与VEGFR-2双阻断在小鼠HCC模型中的疗效。

核心结论

  • 缺氧诱导的内皮细胞特异性DGKG高表达通过ZEB2/TGF-β1轴促进肿瘤血管生成和免疫逃逸,提示内皮DGKG可作为HCC潜在治疗靶点。

研究设计与样本

  • 研究筛选并验证HCC肿瘤血管内皮细胞中DGKG高表达,采用单细胞RNA测序、飞行时间流式细胞术及体内外实验研究内皮DGKG功能,并用多重免疫组化染色和流式细胞术评估肿瘤微环境变化。

主要发现

  • 内皮DGKG促进HCC肿瘤血管生成和免疫抑制性调节性T细胞分化。
  • 缺氧下HIF-1α通过直接结合DGKG启动子区域激活其转录。
  • 上调的DGKG通过招募泛素特异性肽酶16促进ZEB2去泛素化,增加TGF-β1分泌,从而诱导肿瘤血管生成和调节性T细胞分化。
  • 靶向内皮DGKG增强了PD-1与VEGFR-2双阻断的疗效。
  • 在小鼠HCC模型中,抑制内皮DGKG大幅提高抗VEGFR2与抗PD-1双联合治疗疗效,显著抑制HCC恶性进展并改善生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. The tumor microenvironment (TME) contributes to the poor response of patients with HCC to current therapies, while tumor vascular endothelial cells (ECs) are fundamental TME components that significantly contribute to tumor progression. However, the specific functions and mechanisms of tumor vascular ECs in HCC remain unclear. METHODS: We screened and validated diacylglycerol kinase gamma (DGKG) hyper-expression specifically in HCC tumor vascular ECs. Single-cell RNA-sequencing, cytometry by time-of-flight, and in vitro and in vivo studies were performed to investigate the functions of endothelial DGKG. Multiplexed immunohistochemistry staining and flow cytometry were used to evaluate changes in the TME. RESULTS: Functionally, endothelial DGKG promotes tumor angiogenesis and immunosuppressive regulatory T-cell differentiation in HCC. Of significance, we found that HIF-1α activates DGKG transcription by directly binding to its promoter region under hypoxia. Upregulated DGKG promotes HCC progression by recruiting ubiquitin specific peptidase 16 to facilitate ZEB2 deubiquitination, which increases TGF-β1 secretion, thus inducing tumor angiogenesis and regulatory T-cell differentiation. Importantly, targeting endothelial DGKG potentiated the efficiency of dual blockade of PD-1 and VEGFR-2. CONCLUSION: Hypoxia-induced EC-specific DGKG hyper-expression promotes tumor angiogenesis and immune evasion via the ZEB2/TGF-β1 axis, suggesting EC-specific DGKG as a potential therapeutic target for HCC. IMPACT AND IMPLICATIONS: Here, we reported that hypoxia-induced endothelial cell-specific DGKG hyper-expression promotes angiogenesis and immune evasion in HCC by recruiting USP16 for K48-linked deubiquitination and inducing the subsequent stabilization of ZEB2, leading to increased TGF-β1 secretion. Most importantly, endothelial DGKG inhibition greatly improved the efficacy of the dual combination of anti-VEGFR2 and anti-PD-1 treatment in a mouse HCC model, significantly inhibiting the malignant progression of HCC and improving survival. This preclinical study supports the targeting of endothelial DGKG as a potential strategy for precision HCC treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Xu J, Zhou S, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol. 2023. PMID: 37838036. doi:10.1016/j.jhep.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。